CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 50 enrolled
Drug / intervention
Conivaptan +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00478192
NCT00478192Phase 3Completed

A Phase IIIb, Randomized, Double-Blind, Parallel Group, Multi-Center, Study to Assess the Efficacy and Safety of Multiple 30 Minute Infusions of YM087 (Conivaptan) in Subjects With Euvolemic or Hypervolemic Hyponatremia

Cumberland Pharmaceuticals·interventional·Posted May 24, 2007·Updated May 15, 2014

In Brief

A Phase 3 clinical trial evaluating Conivaptan and Placebo for Hyponatremia. Completed, enrolled 50 participants across 26 sites in 2 countries.

Detailed Summary

The study is designed to assess the efficacy and safety of multiple infusions of conivaptan in subjects with euvolemic or hypervolemic hyponatremia

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHyponatremia
CountriesIndia, United States
Collaborators--

Timeline

Phase 3CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedMay 24, 2007
Enrollment StartApr 1, 2007
Primary CompletionAug 1, 2008
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 19.1 years ago

Interventions

Conivaptandrug

premix bag

Placebodrug

premix bag